摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-methyl-chroman-3-one | 25863-99-4

中文名称
——
中文别名
——
英文名称
6-methyl-chroman-3-one
英文别名
6-Methylchroman-3-on;6-methyl-4H-chromen-3-one
6-methyl-chroman-3-one化学式
CAS
25863-99-4
化学式
C10H10O2
mdl
——
分子量
162.188
InChiKey
PGKBMUPQNULSCU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    295.5±29.0 °C(Predicted)
  • 密度:
    1.157±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    6-methyl-chroman-3-one苯肼溶剂黄146 为溶剂, 反应 0.08h, 生成 2-methyl-6,7-dihydro-chromeno[3,4-b]indole
    参考文献:
    名称:
    Chatterjea,J.N. et al., Journal of the Indian Chemical Society, 1969, vol. 46, p. 867 - 870
    摘要:
    DOI:
  • 作为产物:
    描述:
    参考文献:
    名称:
    A New Synthesis of 3-Oxo-3,4-dihydro-2H-1-benzopyrans, 3-Oxo-3,4-dihydro-2H-naphtho[1,2-b]pyran, and 2-Oxo-2,3-dihydro-1H-naphtho[2,1-b]pyran: The Use of Bis[hexafluoroaceto-acetonato]copper(II) in the Cyclization of 1-Diazo-3-aryloxy-2-propanones
    摘要:
    DOI:
    10.1055/s-1984-30805
点击查看最新优质反应信息

文献信息

  • [EN] HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES<br/>[FR] FONGICIDES D'AZOLYL BENZÈNE SUBSTITUÉ PAR HÉTÉROBICYCLE
    申请人:DU PONT
    公开号:WO2011059619A1
    公开(公告)日:2011-05-19
    Disclosed are compounds of Formula 1, including all stereoisomers, N oxides, and salts thereof, wherein Y is a 5-membered, fully or partially unsaturated heterocyclic ring containing 2-4 carbon atoms and 2-3 nitrogen atoms as ring members, the ring substituted with Z on a ring member atom connected through an adjacent single ring member atom to the ring member atom attaching the heterocyclic ring to the phenyl ring of Formula 1, and optionally further substituted with up to 2 substituents independently selected from R5 on carbon atom ring members and from R6 on nitrogen atom ring members; Z is an 8-, 9-, 10- or 11-membered fused heterobicyclic ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon atom ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O)u(=NR7)z, the ring system optionally substituted with substituents independently selected from R8 on carbon atom ring members and from R9 on nitrogen atom ring members; and R1, R2, R3, R4, R5, R6, R7, R8, R9, u and z are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.
    公开的是Formula 1的化合物,包括所有立体异构体、N-氧化物和盐,其中Y是一个5元的、完全或部分不饱和的杂环环,含有2-4个碳原子和2-3个氮原子作为环成员,该环在通过相邻的单环成员原子连接到将杂环环连接到Formula 1的苯环上的环成员原子上与Z取代,并且可选地进一步取代最多2个取代基,独立地从碳原子环成员上的R5和氮原子环成员上的R6中选择;Z是一个8、9、10或11元的融合杂双环环系统,其中环成员从碳原子和1到4个异原子中独立选择,这些异原子最多选择2个O、最多2个S和最多4个N原子,其中最多3个碳原子环成员独立选择自C(=O)和C(=S),硫原子环成员独立选择自S(=O)u(=NR7)z,环系统可选地取代取代基,独立地从碳原子环成员上的R8和氮原子环成员上的R9中选择;以及R1、R2、R3、R4、R5、R6、R7、R8、R9、u和z如披露中所定义。还公开了含有Formula 1的化合物的组合物以及用于控制由真菌病原体引起的植物病害的方法,包括施用本发明的化合物或组合物的有效量。
  • SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS
    申请人:THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLAD
    公开号:US20160326123A1
    公开(公告)日:2016-11-10
    The present invention relates to compounds including but not limited to of any one of formulas Ia, Ib, IIa, IIb, IIIa, IIIb, and IV to VI, VIIa, VIIb, VIIIa, VIIIb and VIIIc as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.
    本发明涉及包括但不限于以下任一式Ia、Ib、IIa、IIb、IIIa、IIIb和IV至VI、VIIa、VIIb、VIIIa、VIIIb和VIIIc的化合物,以及其互变异构体和/或药用可接受的盐、组合物和使用方法。
  • Photochemical behaviour of 3.4-epoxyprecocene-I and related epoxychromans
    作者:G. Ariamala、K.K. Balasubramanian
    DOI:10.1016/s0040-4020(01)89238-3
    日期:1989.1
    A systematic study of photochemical behaviour of 3,4-epoxyprecocene-I and related epoxychromans was undertaken. Upon irradiation in acetone or cyclohexane, 3,4-epoxyprecocene-I was found to undergo photoisomerisation to the corresponding 3-chromanone . In contrast, the photochemical behaviour of analogous 3,4-dihydro-3,4-epoxy-2H-1-benzopyrans 3 was found to be dependent upon the nature of solvent
    进行了系统的研究3,4-epoxyprecocene-I和相关的环氧chromans的光化学行为。在丙酮或环己烷中辐照后,发现3,4-环氧前十烯-1经历光异构化为相应的3-苯并二氢吡喃酮。相反,发现类似的3,4-二氢-3,4-环氧-2H-1-苯并吡喃3的光化学行为取决于溶剂的性质。在环己烯中辐射3导致光脱羰基化导致2,3-二氢苯并呋喃的形成,而在丙酮中辐射导致chramanones的形成。
  • COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA
    申请人:Fratagene Therapeutics Ltd.
    公开号:US20160083358A1
    公开(公告)日:2016-03-24
    The invention provides compositions and methods useful for the treatment of Friedreich's ataxia. In some embodiments, the invention provides compositions and methods useful for inhibiting the ubiquitination of frataxin.
    这项发明提供了用于治疗弗里德莱希共济失调症的组合物和方法。在某些实施例中,该发明提供了用于抑制frataxin泛素化的组合物和方法。
  • Novel Bicyclic Antibiotics
    申请人:Gaucher Berangere
    公开号:US20120040957A1
    公开(公告)日:2012-02-16
    Compounds of formula (I) wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; R1 and R2, independently of one another, represent hydrogen or a substituent selected from hydroxy, halogen, carboxy, amino, C1-C6alkylamino, di(C1-C6alkyl)amino, mercapto, cyano, nitro, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylthio, C1-C6alkylamino-carbonyloxy, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkylcarbonyloxy, C1-C6alkyl-sulfonyloxy, C1-C6heteroalkylcarbonyloxy, C5-C6heterocyclyl-carbonyloxy, C1-C6heteroalkyl, C1-C6heteroalkoxy, wherein heteroalkyl, heteroalkoxy groups or heterocyclyl comprise 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, in which substituents the alkyl moieties are unsubstituted or further substituted by halogeno, cyano, hydroxy, C1-C4alkoxy, C1-C4alkylcarbonyl, C1-C4alkoxycarbonyl, unsubstituted or substituted phenoxy or phenylcarbonyl, unsubstituted or substituted C5-C6heterocyclyl or carboxy; A1 represents a divalent group of one of the formulae —O—(CH 2 ) m —(CH 2 )—, —S—(CH 2 ) m —(CH 2 )— or —(C═O)O—(CH 2 ) m —(CH 2 )—, wherein the (CH 2 ) m moiety is optionally substituted by C1-C4alkyl, C2-C4alkenyl, C3-C6cycloalkyl, C3-C6cycloalkylmethyl, morpholinomethyl, halogen, carboxy, hydroxy, C1-C4alkoxy; C1-C4alkoxyC1-C4alkyl, C1-C4alkoxy(C1-C4alkylenoxy)C1-C4alkyl, benzyloxyC1-C4alkyl, amino, mono- or di-(C1-C4alkyl)amino or acylamino, in which substituents the alkyl moieties can be further substituted by 1 or more fluoro atoms m is 0, 1 or 2, provided that the nunber of atoms in the direct chain between the two terminal valencies of A 1 is at least 3, which group A 1 is linked to A 2 via the terminal (CH 2 )-moiety; A 2 is a group selected from C 3 -C 8 cycloalkylene; saturated and unsaturated 4 to 8 -membered heterocyclodiyl with 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, which group A 2 is unsubstituted or substituted; R 4 represents hydrogen or C 1 -C 4 alkyl; A 3 represents C 1 -C 4 alkylene, C 2 -C 4 alkenylene, >C═O, —C(O)C 1 -C 3 alkylene-, —C(═O)NH—, or a group selected from —C 2 H 4 NH—, —C 2H 4 O—, and —C 2 H 4 S— being linked to the adjacent NR 4 -group via the carbon atom; and G represents aryl or heteroaryl, which is unsubstituted or substituted and n is 0, 1 or 2; or a pharmaceutically acceptable salts, hydrates or solvates thereof are valuable antibacterial agents.
    化合物式(I)中,其中X1、X3、X4和X6分别独立地表示氮原子或CR2,但至少其中一个表示氮原子;X2表示C-H、C-(C1-C6烷基)、C-(C1-C6烷氧基)、C-卤素、C-COOH;X5表示C-H或C-(C1-C6烷基)、C-卤素;R1和R2独立地表示氢或从羟基、卤素、羧基、氨基、C1-C6烷基氨基、二(C1-C6烷基)氨基、巯基、氰基、硝基、C1-C6烷基、C1-C6烷氧基、C1-C6烷基硫基、C1-C6烷基氨基羰氧基、C2-C6烯基、C2-C6炔基、C1-C6烷基羰氧基、C1-C6烷基磺酰氧基、C1-C6杂烷基羰氧基、C5-C6杂环基羰氧基、C1-C6杂烷基、C1-C6杂烷氧基中选择的取代基,其中杂烷基、杂烷氧基或杂环基包括1、2或3个从氮、氧和硫选择的杂原子,在这些取代基中,烷基基团未取代或进一步取代为卤代、氰基、羟基、C1-C4烷氧基、C1-C4烷基羧基、C1-C4烷氧羰基、未取代或取代的苯氧基或苯基羧基、未取代或取代的C5-C6杂环基或羧基;A1表示一个二价基团,其中之一为式之一的基团-O-(CH2)m-(CH2)-、-S-(CH2)m-(CH2)-或-(C═O)O-(CH2)m-(CH2)-,其中(CH2)m基团可以选择地被C1-C4烷基、C2-C4烯基、C3-C6环烷基、C3-C6环烷基甲基、吗啉基甲基、卤素、羧基、羟基、C1-C4烷氧基取代;C1-C4烷氧基C1-C4烷基、C1-C4烷氧基(C1-C4烷氧基)C1-C4烷基、苄氧基C1-C4烷基、氨基、单取代或双取代(C1-C4烷基)氨基或酰基氨基,在这些取代基中,烷基基团可以进一步取代1个或多个氟原子,m为0、1或2,前提是A1的两个端面价之间的直链原子数至少为3,该基团A1通过端面(CH2)基团与A2相连;A2是选择自C3-C8环烷基、饱和和不饱和的1、2或3个从氮、氧和硫选择的杂环二基,该基团A2未取代或取代;R4表示氢或C1-C4烷基;A3表示C1-C4烷基、C2-C4烯基、>C═O、-C(O)C1-C3烷基、-C(═O)NH-或选择自-C2H4NH-、-C2H4O-和-C2H4S-的基团,通过碳原子与相邻的NR4基团相连;G表示未取代或取代的芳基或杂芳基,其中n为0、1或2;或其药学上可接受的盐、水合物或溶剂。这些化合物是有价值的抗菌剂。
查看更多